Today: 7 November 2025
Subscribe
ConocoPhillips (COP) beats Q3, hikes dividend 8%, lifts 2025 output; Willow budget raised to up to $9B — Nov. 6, 2025
 ·  ·  ·  ·  · 

ConocoPhillips (COP) beats Q3, hikes dividend 8%, lifts 2025 output; Willow budget raised to up to $9B — Nov. 6, 2025

by
6 November 2025

ConocoPhillips (NYSE: COP) delivered a news‑packed earnings day: the U.S. independent beat third‑quarter profit expectations, raised its full‑year production guidance, increased its quarterly dividend by 8% to $0.84, and updated the cost outlook for its Willow project in Alaska to $8.5–$9.0 billion. Management also released preliminary 2026 guidance with lower planned capital and operating costs and flat‑to‑modest production growth. [1]

The quick take

  • Earnings beat: Adjusted EPS $1.61 vs. ~$1.43 consensus (LSEG), helped by higher output and cost discipline despite softer crude benchmarks. [2]
  • Dividend raised: Ordinary dividend up 8% to $0.84 per share; payable Dec. 1, 2025 to shareholders of record Nov. 17, 2025. [3]
  • Production & guidance: Q3 production ~2.399 MMBOED; full‑year 2025 guidance raised to 2.375 MMBOED; Q4 outlook 2.30–2.34 MMBOED. [4]
  • Costs: 2025 adjusted operating cost guidance cut to $10.6B; 2026 prelim guidance: capex ~$12B, adjusted opex ~$10.2B, 0–2% underlying production growth. [5]
  • Projects: Willow total project capital updated to $8.5–$9.0B; first oil early 2029. LNG capital reduced to ~$3.4B after a Port Arthur credit; NFE first LNG expected 2026. [6]

By the numbers (Q3 2025)

  • Production:2,399 MBOED total; Lower 48: 1,528 MBOED
    — Delaware 686, Midland 196, Eagle Ford 403, Bakken 200 MBOED. [7]
  • Profitability: EPS $1.38 (GAAP); adjusted EPS $1.61. [8]
  • Cash generation:$5.9B cash provided by operating activities; $5.4B CFO (ex‑WC). [9]
  • Shareholder returns:$2.2B returned (≈ $1.3B buybacks + $1.0B dividend) in Q3. [10]
  • Realized price:$46.44/BOE, ~14% below Q3 2024. [11]
  • Balance sheet:$6.6B cash & short‑term investments at quarter‑end. [12]

What changed today — and why it matters

Earnings beat and stronger 2025 outlook. ConocoPhillips outpaced expectations on adjusted profit thanks to higher production and lower operating costs. The company also lifted full‑year production guidance and trimmed 2025 cost guidance, signaling better capital efficiency heading into year‑end. Reuters highlighted the beat versus consensus and noted the company’s integration and cost savings from the Marathon Oil acquisition helped offset ~13% year‑over‑year declines in benchmark prices. [13]

Bigger base dividend. COP raised its quarterly ordinary dividend by 8% to $0.84, maintaining its pledge of top‑quartile dividend growth. The payout is payable Dec. 1 to holders of record Nov. 17—dates that matter for income investors tracking ex‑dividend timelines. [14]

2026 glide path: doing more with less. Preliminary 2026 guidance calls for ~$12B capex (down vs. 2025), ~$10.2B adjusted operating costs, and 0–2% underlying production growth—consistent with a “returns‑first” playbook as large projects ramp and acquisition synergies mature. [15]

Portfolio & project updates

  • Willow (Alaska): Total project capital updated to $8.5–$9.0B, reflecting inflation and localized North Slope/marine cost escalation; first oil now early 2029. [16]
  • LNG strategy: After a $0.6B Port Arthur credit, total LNG project capital is ~$3.4B and ~80% complete; first LNG from Qatar NFE expected 2026. Long‑term SPAs signed at Port Arthur LNG Phase 2 and Rio Grande LNG Train 5 (20‑year terms). [17]
  • Portfolio high‑grading: YTD 2025 dispositions exceed $3B; COP remains on track for $5B through 2026 (including the Q4 closing of $1.3B Anadarko Basin assets). [18]

Regulatory watch: Marathon Oil settlement touches the COP orbit

Separately today, Marathon Oil—acquired by ConocoPhillips in November 2024—reached a $241 million settlement over alleged air‑pollution violations on North Dakota’s Fort Berthold Indian Reservation. The deal includes a record $64.5M Clean Air Act penalty and $177M in environmental upgrades, which are expected to reduce emissions by ~2.25 million tons CO₂‑equivalent over five years. The proposed consent decree is subject to a 30‑day public‑comment period; Marathon says it began compliance work in 2022. [19]

Context: ConocoPhillips completed its acquisition of Marathon Oil in 2024, integrating those assets into COP’s portfolio. [20]

What to watch next

  • Earnings call: Management hosts its Q3 2025 call today at 12:00 p.m. ET—a venue to listen for details on Willow phasing, LNG commercialization, and 2026 capital priorities. [21]
  • Dividend timeline: Record date Nov. 17, 2025; payment Dec. 1, 2025. [22]
  • Q4 production cadence: Company targets 2.30–2.34 MMBOED; any updates to Lower 48 activity or international turnarounds could nudge the range. [23]
  • Asset sales & synergy track: Management reiterated progress toward $5B in dispositions by year‑end 2026 and sustained operating‑cost improvements following the Marathon integration. [24]

Editorial notes for readers (Google News/Discover)

  • Source transparency: Financial figures, guidance, project milestones, dividend dates, and portfolio updates come from ConocoPhillips’ official Q3 2025 news release and SEC 8‑K filed today. Independent confirmation of the earnings beat and quarter‑ahead production range is from Reuters. The regulatory item regarding Marathon Oil stems from a Reuters report on today’s announced settlement. [25]

This article is for information purposes only and is not investment advice.

ConocoPhillips Smashes Earnings: Efficiency Gains Drive Growth
Watch this video on YouTube.

References

1. www.conocophillips.com, 2. www.reuters.com, 3. www.conocophillips.com, 4. www.conocophillips.com, 5. www.conocophillips.com, 6. www.conocophillips.com, 7. www.conocophillips.com, 8. www.conocophillips.com, 9. www.conocophillips.com, 10. www.conocophillips.com, 11. www.conocophillips.com, 12. www.conocophillips.com, 13. www.reuters.com, 14. www.conocophillips.com, 15. www.conocophillips.com, 16. www.conocophillips.com, 17. www.conocophillips.com, 18. www.conocophillips.com, 19. www.reuters.com, 20. www.conocophillips.com, 21. www.conocophillips.com, 22. www.conocophillips.com, 23. www.reuters.com, 24. www.conocophillips.com, 25. www.conocophillips.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

  1. Brighthouse Financial (BHF) to Be Acquired by Aquarian Capital for $4.1B at $70/Share; Stock Jumps — Nov. 6, 2025
  2. HubSpot (HUBS) Plunges ~18% After Q3 Beat: Raised 2025 Guidance, New AI Push, and Meta’s Clara Shih Joins the Board [Nov. 6, 2025]
  3. SiTime (SITM) Stock Jumps After Q3 2025 Beat; Company Guides Q4 Revenue to $100–$103M on AI Data‑Center Demand
  4. Hecla Mining (HL) Soars on Record Q3 2025: $409.5M Revenue, $0.15 EPS, Dividend Declared — What to Know Today (Nov 6, 2025)

Stock Market Today

  • Figs (NYSE:FIGS) Q3 Beat on Revenue, EBITDA; Shares Jump ~16% on Strong Results
    November 7, 2025, 12:36 AM EST. Figs (NYSE:FIGS) posted a stronger-than-expected Q3 CY2025 as revenue rose to $151.7 million, up 8.2% YoY and ahead of estimates of $142.5 million. The company reported an Adjusted EPS of $0.05, well above consensus of $0.02, and Adjusted EBITDA of $18.85 million versus $12.38 million expected. The operating margin improved to 6.4% from -6.2% a year earlier. However, free cash flow margin slipped to 0.4% from 13.1% in the year-ago quarter. Active customers reached 2.78 million, up 108k YoY. With a $1.24 billion market cap, the stock's move reflected investor enthusiasm as shares jumped ~16% following the results. Sell-side revenue guidance looks flat over the next 12 months, suggesting some near-term headwinds despite profitability gains.
  • Globus Medical Q3 Beat Lifts Guidance; GMED Stock Rises on Strong Results
    November 7, 2025, 12:34 AM EST. Globus Medical (GMED) reported a solid Q3 CY2025, with revenue of $769 million, up 22.9% YoY, and a 4.7% beat versus estimates. Its non-GAAP EPS of $1.18 eclipsed consensus by 53.4%, and Adjusted EBITDA reached $252.6 million, a beat of about 27.3%. The company lifted its full-year revenue guidance to a midpoint of $2.88 billion and raised Adjusted EPS to $3.80. The operating margin expanded to 17.9% from 7.7%, while free cash flow margin rose to 27.8%. Constant-currency growth was 22.3% YoY. With operations in 64 countries and a broad spine/orthopedic/neurosurgical portfolio, the quarter reinforces a durable growth trajectory for GMED.
  • NVIDIA Stock Drops 3.7% as Insiders Sell Big: CFO Colette Kress and CEO Jen Hsun Huang Trim Stakes
    November 7, 2025, 12:32 AM EST. NVDA shares fell about 3.7% on Thursday after notable insider selling surfaced. The stock traded as low as $186.38 and was last at $188.08, with about 220,077,580 shares changing hands vs. the 226,128,344 average. CFO Colette Kress sold 20,000 shares at $208.33 (≈$4.17 million), cutting her stake to 123,060 shares. A second sale of 27,640 shares at the same price reduced ownership by ~0.97% to 2,828,122 shares (≈$589.2 million). CEO Jen Hsun Huang sold 25,000 shares at $207.91, leaving him with 69,733,203 shares (≈$14.5 billion). On the sentiment side, analysts remain constructive: Truist, Piper Sandler, Jefferies, Citigroup, and Bank of America raised targets or reiterated Buy/Overweight ratings. Market consensus shows a mix: 5 Strong Buy, 41 Buy, 2 Hold, 1 Sell.
  • Tesla 2026 Supercycle: 5 Catalysts That Could Ignite TSLA
    November 7, 2025, 12:30 AM EST. Tesla's 2026 thesis centers on five bullish catalysts that could lift TSLA despite a transitional period. The piece argues that stocks move on future-forward information, not just current price, and that Tesla's strength lies in disruptive product announcements and software-led upgrades. The five catalysts highlighted include the Robotaxi network powered by FSD and a Cybercab rollout; ongoing cash generation even before new products fully scale; a shift away from the legacy EV business toward high-margin software and services; a broader product and AI roadmap that re-accelerates growth; and potential regulatory, manufacturing, or market catalysts that could force a valuation re-rating. If Musk's vision translates into realized deployments and expanding margins, the stock could experience a large valuation re-rating.
  • Evolent Health Beats Q3 Revenue, Stock Jumps 14.8% on Mixed Results
    November 7, 2025, 12:28 AM EST. Evolent Health (EVH) beat Wall Street on Q3 revenue, generating $479.5 million vs $467.3 million estimates, though year-over-year demand declined 22.8%. The adjusted EPS of $0.05 missed estimates of $0.11 (a 52.5% miss). Adjusted EBITDA came in at $38.96 million, slightly above consensus ($37.67 million). The company guided Q4 revenue of $467 million at the midpoint, below calls for about $472.9 million, and full-year EBITDA guidance of $149 million vs $151.7 million expected. Operating margin improved to 0.2% from -2.6% a year ago; free cash flow margin steady at 1.4%. CEO Seth Blackley cited new contracts (13 this year) and a planned ECP transaction to reduce debt, with a longer-term forecast of $2.5 billion revenue in 2026. Shares rose roughly 14.8%.
MMTec (MTC) soars 627% and then whipsaws pre‑market as Nasdaq delisting clock ticks — What to know today (Nov. 6, 2025)
Previous Story

MMTec (MTC) soars 627% and then whipsaws pre‑market as Nasdaq delisting clock ticks — What to know today (Nov. 6, 2025)

e.l.f. Beauty (ELF) plunges as tariff hit and soft FY‑2026 outlook overshadow Rhode boost: what to know today (Nov. 6, 2025)
Next Story

e.l.f. Beauty (ELF) plunges as tariff hit and soft FY‑2026 outlook overshadow Rhode boost: what to know today (Nov. 6, 2025)

Related Articles

Go toTop